Literature DB >> 23445338

Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.

Christoph Tinchon, Eva Hubmann, Angelika Pichler, Felix Keil, Martin Pichler, Hans Rabl, Martin Uggowitzer, Kurt Jilek, Gerhard Leitner, Thomas Bauernhofer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23445338     DOI： 10.3109/0284186X.2013.771821

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  16 in total

1.  Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer.

Authors:  Xifeng Xu; Qiong Wu; Zhen Wang; Song Zheng; Ke Ge; Changku Jia
Journal:  Clin Exp Med       Date:  2018-11-29       Impact factor: 3.984

2.  Treatment of borderline resectable pancreatic cancer.

Authors:  Amanda B Cooper; Ching-Wei D Tzeng; Matthew H G Katz
Journal:  Curr Treat Options Oncol       Date:  2013-09

3.  Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report.

Authors:  Maria Celeste Palmarocchi; Ruben Carlo Balzarotti Canger; Piercarlo Saletti
Journal:  Oncol Lett       Date:  2017-04-11       Impact factor: 2.967

4.  Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.

Authors:  Quisette P Janssen; Stefan Buettner; Mustafa Suker; Berend R Beumer; Pietro Addeo; Philippe Bachellier; Nathan Bahary; Tanios Bekaii-Saab; Maria A Bali; Marc G Besselink; Brian A Boone; Ian Chau; Stephen Clarke; Mary Dillhoff; Bassel F El-Rayes; Jessica M Frakes; Derek Grose; Peter J Hosein; Nigel B Jamieson; Ammar A Javed; Khurum Khan; Kyu-Pyo Kim; Song Cheol Kim; Sunhee S Kim; Andrew H Ko; Jill Lacy; Georgios A Margonis; Martin D McCarter; Colin J McKay; Eric A Mellon; Sing Yu Moorcraft; Ken-Ichi Okada; Alessandro Paniccia; Parag J Parikh; Niek A Peters; Hans Rabl; Jaswinder Samra; Christoph Tinchon; Geertjan van Tienhoven; Eran van Veldhuisen; Andrea Wang-Gillam; Matthew J Weiss; Johanna W Wilmink; Hiroki Yamaue; Marjolein Y V Homs; Casper H J van Eijck; Matthew H G Katz; Bas Groot Koerkamp
Journal:  J Natl Cancer Inst       Date:  2019-08-01       Impact factor: 13.506

5.  Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.

Authors:  Matthew H G Katz; Qian Shi; Syed A Ahmad; Joseph M Herman; Robert de W Marsh; Eric Collisson; Lawrence Schwartz; Wendy Frankel; Robert Martin; William Conway; Mark Truty; Hedy Kindler; Andrew M Lowy; Tanios Bekaii-Saab; Philip Philip; Mark Talamonti; Dana Cardin; Noelle LoConte; Perry Shen; John P Hoffman; Alan P Venook
Journal:  JAMA Surg       Date:  2016-08-17       Impact factor: 14.766

6.  Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer.

Authors:  M Stotz; A Gerger; F Eisner; J Szkandera; H Loibner; A L Ress; P Kornprat; W AlZoughbi; W A Zoughbi; F S Seggewies; C Lackner; T Stojakovic; H Samonigg; G Hoefler; M Pichler
Journal:  Br J Cancer       Date:  2013-06-25       Impact factor: 9.075

7.  Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients.

Authors:  J Szkandera; M Stotz; G Absenger; T Stojakovic; H Samonigg; P Kornprat; R Schaberl-Moser; W Alzoughbi; C Lackner; A L Ress; F S Seggewies; A Gerger; G Hoefler; M Pichler
Journal:  Br J Cancer       Date:  2013-11-07       Impact factor: 9.075

8.  Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients.

Authors:  Michael Stotz; Joanna Szkandera; Julia Seidel; Tatjana Stojakovic; Hellmut Samonigg; Daniel Reitz; Thomas Gary; Peter Kornprat; Renate Schaberl-Moser; Gerald Hoefler; Armin Gerger; Martin Pichler
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

9.  SEOM Clinical Guideline for the treatment of pancreatic cancer (2016).

Authors:  R Vera; E Dotor; J Feliu; E González; B Laquente; T Macarulla; E Martínez; J Maurel; M Salgado; J L Manzano
Journal:  Clin Transl Oncol       Date:  2016-11-28       Impact factor: 3.405

10.  External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients.

Authors:  Joanna Szkandera; Michael Stotz; Florian Eisner; Gudrun Absenger; Tatjana Stojakovic; Hellmut Samonigg; Peter Kornprat; Renate Schaberl-Moser; Wael Alzoughbi; Anna Lena Ress; Friederike Sophia Seggewies; Armin Gerger; Gerald Hoefler; Martin Pichler
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.752
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.